一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Journal of Controlled Release >>article
Journal of Controlled Release

Journal of Controlled Release

IF: 10.5
Download PDF

Dual-targeted alpha therapy mitigates prostate cancer and boosts immune checkpoint blockade therapy

Published:3 April 2025 DOI: 10.1016/j.jconrel.2025.113686
Juan Sun , Jiangtao Yang , Jiakun Guo , Lei Tao , Bin Xu , Guanglin Wang , Fenghua Meng , Zhiyuan Zhong

Abstract

Alpha radionuclide with a high emitting energy and short emitting range has emerged as a new tool for the treatment of advanced tumors; however, its clinical usage stringently depends on delivery vehicle. Here, we report on Sigma-1 receptor and PSMA dual-specific peptide with efficient 225?actinium labeling (225Ac-S1R/PSMA-P) for targeted alpha therapy and alpha-immunotherapy of murine prostate tumor. 225Ac-S1R/PSMA-P with a high specific activity and radiostability exhibited upgraded cell binding and uptake while diminished efflux in RM1-PSMA+ cancer cells. Intriguingly, 225Ac-S1R/PSMA-P afforded a peak uptake of 34.7?±?3.2 %ID/g and elevated the radioactivity in the tumor over 7?days, with a tumor/kidney ratio of 12.2?±?1.2 and minimal deposition in blood and other normal tissues like liver and muscle. A single injection of 225Ac-S1R/PSMA-P effectively shrank large LNCaP-FGC tumors at 1.85 or 5.5?kBq, and completely eradicated highly malignant murine RM1-PSMA+/RM1 tumors at 33.3?kBq. We further showed that 225Ac-S1R/PSMA-P at a low dose of 3.7?kBq could boost immune checkpoint blockade therapy of murine RM1-PSMA+/RM1 tumor, leading to 5 out of 7 mice tumor-free that showed durable antitumor immune memory. 225Ac-S1R/PSMA-P with excellent targeting and immune activation ability has a great clinical potential for treating advanced prostate cancer patients.

Substances (4)

Materials
Procduct Name CAS Molecular Formula Supplier Price
PSMA-617 1702967-37-0 C49H71N9O16 49 suppliers Inquiry
PSMA-617 1702967-37-0 C49H71N9O16 49 suppliers Inquiry
PSMA-617 1702967-37-0 C49H71N9O16 49 suppliers Inquiry
PSMA-617 1702967-37-0 C49H71N9O16 49 suppliers Inquiry

Similar articles

IF:3

A comprehensive review on Brigatinib – A wonder drug for targeted cancer therapy in non-small cell lung cancer

Saudi Pharmaceutical Journal Silky Bedi , Shah A. Khan ,etc Published: 1 September 2018
IF:15.1

Pectin in cancer therapy: A review

Trends in Food Science & Technology Wenbo Zhang , Ping Xu ,etc Published: 1 August 2015
正镶白旗| 宁化县| 砚山县| 皮山县| 县级市| 徐汇区| 萨嘎县| 专栏| 来宾市| 东乡| 运城市| 延安市| 琼结县| 临沂市| 石家庄市| 扶绥县| 当雄县| 密云县| 马山县| 遂昌县| 六盘水市| 崇明县| 西林县| 闸北区| 绥芬河市| 沁阳市| 钦州市| 岗巴县| 陇川县| 巢湖市| 雅安市| 高青县| 寻乌县| 广水市| 射阳县| 衡山县| 岳池县| 友谊县| 南和县| 安乡县| 凌海市|